TP53 and ovarian carcinoma: Consequently, it is apparent that there are drugs for which the p53 background does not impact drug-sensitivity; in the present work we provide evidence that mifepristone behaves in that manner, inhibiting growth and triggering death of ovarian cancer cells which have been largely described as having different p53 genetic statuses (Table 1).